Navigation Links
FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
Date:9/21/2007

Regenerating Damaged Cardiac Tissue Is Significant for the Treatment of Cardiovascular Disease

BOCA RATON, Fla., Sept. 21 /PRNewswire-USNewswire/ -- Florida Atlantic University received U.S. patent no. 10/822,496, "Promoting Cardiac Cell Differentiation," based on an invention which induces and restores cardiac muscle function. The invention was discovered by FAU researcher and vice president for research, Dr. Larry F. Lemanski and his postdoctoral fellow, Dr. Chi Zhang. Their research has focused on understanding the mechanisms that regulate myocardial (heart muscle mass) cell differentiation and myofibrillogenesis (the process by which proteins in the heart are changed into heart muscle cells) in the developing heart. From their findings, these researchers hope to repair myocardial deficiencies in the human heart which are caused by either congenital heart defects or heart attacks.

Lemanski, Zhang and their colleagues at FAU have been looking at the cellular, molecular and genetic signals that affect heart cell differentiation and regulation of the synthesis of contractile proteins within cardiac muscle cells that allows cells to contract. Identifying the biological factors that induce this differentiation would be a major step forward in the development of therapies.

"When an individual has a heart attack with a significant region of the heart muscle damaged, recovery to pre-heart attack levels are rarely achieved," said Lemanski. "Strategies to regenerate damaged cardiac tissue could be significant in the treatment of cardiovascular disease."

Adult heart muscle cells lack the ability to regenerate following injury because of terminal differentiation. The number of heart cells is determined at birth and once damaged cannot repair themselves. Furthermore, many congenital abnormalities are thought to be caused by improper signaling between cells and tissues as a result of abnormal genes.

Observing cardiac mutant Mexican axolotls (salamanders), these researchers identified a major protein that was deficient in these axolotl hearts which prevented the organization of myofibrils (contractile machinery) and the ability to beat. Using these findings, Lemanski, Zhang and their colleagues were able to show that this mutant defect could be rescued by treatment with specific and unique RNA (ribonucleic acid) derived from the anterior endoderm (gut) of normal animal model embryos. They cloned the gene for this specific RNA, synthesizing a "bioactive" RNA that is capable of rescuing mutant hearts by promoting the development and differentiation of contractile cardiac muscle cells from non-contractile, pre-cardiac, non-muscle cells.

Lemanski termed this discovery as "myofibrillogenesis inducing RNA" or MIR. Additional studies have shown that humans have a similar, most likely identical, mechanism as the axolotls, for the formation of functional contracting heart muscle cells. It may also be possible to produce new functional cardiac muscle tissue in areas of human hearts that require these cells and tissues for restoration of normal function.

"The issuance of this patent marks a tremendous achievement for Drs. Lemanski and Zhang as well as FAU, especially at a time when the United States Patent and Trademark Office (USPTO) continues to implement a tougher examination process," said Stephen Nappi, director of technology transfer and assistant vice president for research at FAU. "To continue to build upon this momentum, we will aggressively seek to identify and recruit the right company to help us bring this important invention to patients with cardiovascular disease."

Taken into the clinical setting, a human version of this MIR may allow patients who have suffered from heart attacks and have impaired physical activities due to scar tissue in their hearts to have those scarred areas replaced with new cardiac muscle. This treatment would therefore enable them to return to pre-heart attack activity levels. In addition, children who are born with congenital heart defects could have those defective areas of their hearts repaired without a series of invasive surgical operations.

According to the American Heart Association, cardiovascular diseases (CVD) rank as America's number one killer, claiming the lives of over 36 percent of the more than 2.4 million who die each year in the United States. Furthermore, 79.4 million people in the U.S. have some form of CVD. These include diseases of the heart, stroke, high blood pressure, congestive heart failure, congenital cardiovascular defects, hardening of the arteries and other diseases related to the circulatory system.

Lemanski also serves as president and chair of the FAU Research Corporation and is a professor of biomedical sciences in the Charles E. Schmidt College of Biomedical Science and a professor of biology and chemistry in the Charles E. Schmidt College of Science at FAU. He is a prolific researcher in the field of cellular, molecular and developmental biology and has numerous research publications, book chapters and proceedings to this credit, as well as many presentations at national and international conferences.

Florida Atlantic University opened its doors in 1964 as the fifth public university in Florida. Today, the University serves more than 26,000 undergraduate and graduate students on seven campuses strategically located along 150 miles of Florida's southeastern coastline. Building on its rich tradition as a teaching university, with a world-class faculty, FAU hosts nine colleges: the Dorothy F. Schmidt College of Arts & Letters, the Charles E. Schmidt College of Biomedical Science, the Charles E. Schmidt College of Science, the Christine E. Lynn College of Nursing, the Harriet L. Wilkes Honors College, the Barry Kaye College of Business and the Colleges of Education, Engineering & Computer Science, and Architecture, Urban & Public Affairs.

This news release was issued on behalf of Newswise (TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE FLORIDA ATLANTIC UNIVERSITY
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results
7. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
8. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
9. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
10. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
11. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a Makro ... list for its expertise in eClinical Solutions. DDi has built its solution competency ... needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory and ...
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
Breaking Medicine News(10 mins):